CHEMICALSEXPORTSCAPEXCDMOCHINA+1

India Chemicals: The 18% Tariff Deal Opens a ₹40,000 Cr Export Window — But Three Companies Will Capture 70% of It

4 May 2026·9 min read·Free Report

30-second version

1.Aarti Industries hit a 52-week high of ₹523 on May 2 after the US-India trade deal confirmation; SRF's fluorochemicals segment EBIT margin recovered to ~22% in Q3 FY26 from a low of 14% in Q1 FY25 — the earnings trough is behind us, the capex payoff is starting.
2.DIIs have net bought ₹2,400 Cr worth of specialty chemicals stocks in April 2026, reversing eight months of net selling; FIIs remain underweight but positioned for re-entry as the trade deal removes the tariff overhang that kept them out since late 2024.
3.The sector trades at a blended 28x trailing PE — a 12% discount to its 5-year average of 32x — which is the first time in three years that you are buying the China+1 structural story at a genuine discount rather than paying up for it.

01What's happening

The US-India bilateral trade framework finalised in late April 2026 sets a 18% blanket tariff cap on Indian chemical exports to the US, replacing the MFN-equivalent rates that had climbed as high as 25-27% on specific agrochemical intermediates under the Trump 2.0 tariff schedule. This is a direct margin unlock: for companies like Aarti Industries and PI Industries, the US accounts for 22-28% of exports, and a 7-9 percentage point tariff reduction drops almost entirely to the bottom line on products where India already has a 15-20% cost advantage over China. Meanwhile, SRF reported Q3 FY26 consolidated EBIT of ₹612 Cr, with the specialty chemicals segment margins recovering to 21.8% versus 13.9% a year ago — the fluorochemicals inventory destocking that crushed FY25 numbers is now definitively over. Navin Fluorine's Q4 FY26 CDMO order book stood at ₹1,850 Cr with an active pipeline of 24 molecules, seven of which are in Phase III trials — at historical conversion rates, two to three molecules will reach commercial scale by FY28. Deepak Nitrite's Dahej phenolics expansion (90,000 MTPA) achieved 78% utilisation in Q3 FY26, ahead of the internal 70% target, and management guided for 90%+ by Q2 FY27. Japanese chemical firms including Sumitomo Chemical and Mitsubishi Chemical have signed MoUs with GIDC Gujarat for dedicated manufacturing blocks — a concrete data point behind the China+1 narrative rather than a conference slide. Atomgrid's new Bengaluru R&D centre, announced in April 2026, adds another Western-funded validation that India can handle complex molecular chemistry, not just commodity toll manufacturing.

02Why this matters for your portfolio

Specialty chemicals is the one sector in India where the structural tailwind — China+1 sourcing, CDMO growth, agrochemical genericisation — actually improves earnings quality, not just revenue. ROCE for the top five listed players averaged 18.2% in FY23, dropped to 14.6% in FY25 during the destocking cycle, and is tracking back toward 19-21% in FY26-27 as utilisation normalises — that recovery in capital efficiency is what the market is only partially pricing. The total addressable market for Indian specialty chemicals exports is estimated at $35-40 billion by FY30 versus $12 billion today; even a conservative 18% CAGR gets you to $25 billion, and Indian capacity additions are tracking to capture a disproportionate share because Chinese producers are losing pricing power on fluorinated compounds and agrochemical intermediates specifically. For a retail investor with a 2-3 year horizon, the entry logic is straightforward: you are buying the cycle at a trough-to-recovery inflection with a policy tailwind that removes a 9-month overhang, at valuations that are below 5-year averages for the first time since 2020. PI Industries deserves specific mention — its CSA (contract research and manufacturing) revenue grew 19% YoY to ₹5,840 Cr in FY26, and its order book of $1.6 billion (roughly ₹13,400 Cr) represents 2.3x trailing revenue, a coverage ratio that makes FY27-28 earnings highly visible. The EU-India Free Trade Agreement, which entered final-stage negotiations in early 2026, is the next potential catalyst — EU chemical imports from India attract 4-6.5% tariffs currently, and elimination would make Indian CDMO economics compelling for European pharma.

03Valuation check

Current multiples vs. 5-year averages. Verdict based on trailing twelve months earnings.

043 stocks worth watching

Fundamentally sound names with a clear thesis. Not buy/sell recommendations.

05Contrarian take

The bear case — what the bulls are missing

Here's what the bulls are missing: the China+1 narrative for agrochemical intermediates is running directly into a counter-cycle where Chinese producers — specifically Jiangsu Yangnong and Shandong Luba — are dumping chlorpyrifos and acephate intermediates at 30-35% below production cost to preserve market share, and Indian players including UPL's Atul Ltd supply chain and smaller Ankleshwar manufacturers are already being undercut on spot contracts. Aarti Industries' chlorobenzene derivatives business, which contributes ~18% of revenue, faces exactly this dynamic — the toluene diisocyanate (TDI) intermediate chain is in a global overcapacity situation with Chinese exports up 22% in CY2025, and Aarti's volumes in this segment have been flat for six consecutive quarters despite the plant running at full capacity. SRF's HFC refrigerant business faces a structural cliff: the Kigali Amendment phase-down of HFC-32 and HFC-125 accelerates from 2029, and SRF has ₹3,200 Cr of fluorochemicals capex tied to products that will lose 40% of their addressable market within five years — management's pivot toward fluoropolymers is the right call but is three years from generating meaningful EBIT. And the CDMO story, while real, is being priced as if conversion from pipeline to commercial is a certainty: historically, fewer than 30% of Phase II molecules that Indian CDMOs add to their order book reach commercial manufacturing, making the ₹1,800-2,000 Cr CDMO order books at Navin Fluorine and Divi's Laboratories significantly less bankable than they appear on a broker's sum-of-the-parts.

06Sources

Primary sources only · No broker reports

Enjoyed this report?

Get a new one every Monday.

Subscriber plans start at ₹499/month. Includes full archive, valuation tables, and watchlists.

See Pricing Plans →